|
|
Free Trial
Description: Julie Bryant is GeneGo VP Business Development/Sales. With a Lead411 subscription, GeneGo email addresses ( @genego.com ) of the executives are viewable. Other information includes Julie Bryant email, phone, and extension.
We provide information from your LinkedIn network, see company profile, and soon we will be showing twitter and facebook profiles as well. Typical management titles include VP, Chief, Vice President, Director, manager, & more. Similar names to Bryant can be found at Executive Directory - Bryant.
|
Add Julie Bryant Information
Site Reference: http://www.genego.com/pressReleases.php#2006-08-08
Julie Bryant GeneGo’s VP of Business development. “We are proud to have them as an institution customer and a Center of Excellence. We have a large development program in the area of cancer system biology tools supported by NCI and we are glad to see this work appreciated by some of the best oncology professionals in the world working at MD Anderson.” Download this press release in PDF format. UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE BECOMES A GENEGO CENTER OF EXCELLENCE St. Joseph, Michigan, July 15th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, today announced that the University of Miami Miller School of Medicine has become a certified GeneGo Center of Excellence (COE). Miller School of Medicine researchers will have access to GeneGo’s MetaCore, training and advanced support. COE will provide a pathway analysis environment and support for all Vice President of Business Development at GeneGo. “The school of medicine works with one million patients annually and it is encouraging that we can help them to improve their quality of life.” Download this press release in PDF format. YALE KECK MICROARRAY CENTER BECOMES A GENEGO CENTER OF EXCELLENCE St. Joseph, MI. July 8th, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that Keck Microarray Center at Yale has become a certified GeneGo Center of Excellence (COE). Yale researchers will have access to GeneGo’s MetaCore, training and advanced support. The W. M. Keck Foundation Biotechnology Resource Laboratory (Keck Lab), one of the largest biotechnology laboratories of its kind in academia, is a world leader in the field of genomics and proteomics. The Keck Microarray Resource is also a part of the NIH-Neuroscience supported Yale Microarray Center for Research on the Nervous system. The GeneGo’s VP of Business development. “We are very pleased to have them as a GeneGo Center of Excellence.” Download this press release in PDF format. VTT TECHNICAL RESEARCH CENTRE OF FINLAND LICENSES METACORE FROM GENEGO FOR CANCER RESEARCH AND DIAGNOSTICS St. Joseph, MI. June 24th, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that VTT has licensed MetaCore TM . VTT develops novel high-throughput methods for cancer research, drug discovery and diagnostics. The focus is in investigating mechanisms of cancer development and progression, identification of therapeutic targets and exploration of the mechanism of action of anti-cancer compounds. VTT will utilize MetaCore and MetaDrug in high-throughput compound screening, RNA interference experiments, cell biology and bioinformatics projects to identify pathways and networks important in translational cancer research. There are 85 researchers and staff members working in VTT’s Medical Biotechnology Knowledge Centre in Turku. The research GeneGo’s VP of Business development. “We have seen a growing need for analysis platforms focused in disease areas recently. We responded by developing disease pathway ontologies, biomarker and drug databases and new interactome analysis tools. We are pleased that our expertise in cancer is appreciated by professional molecular oncologists at VTT.” Download this press release in PDF format. GENEGO IS AWARDED NCI GRANT FOR DEVELOPMENT OF SYSTEMS BIOLOGY PLATFORM FOR INTEGRATIVE DATA ANALYSIS IN CANCER St Joseph, Michigan, June 17th, 2008 - GeneGo Inc., a leading provider of databases, software and services in systems biology, announced today that they were awarded a Phase I SBIR from National Cancer Institute (NCI) for the development of a platform for functional data analysis in cancer. GeneGo will collaborate with investigators at Dana- Farber Cancer Institute, Boston on the project. The system, MetaMiner (Oncology) will combine pathway and network analysis tools, act VP business development. " We have a lot of expertise in this area that is reflected in our grants and publications in Science and Cancer cell". Download this press release in PDF format. GENEGO EXTENDS AGREEMENT WITH MERCK & CO., INC. St. Joseph, Michigan, June 3rd, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Merck & Co., Inc. has extended its global enterprise agreement. This agreement provides Merck with access to GeneGo’s content through MetaBase which includes access to MetaCore and MetaDrug content and GeneGo’s internal database of disease biomarkers. “Effective use of powerful systems biology data mining & analysis solutions have become an essential component of modern day drug discovery and development,” said Julie Bryant, VP business development. "Merck is one of our first customers and we are pleased that they have chosen to renew and extend VP business development. “Hong Kong is a very sophisticated market with top notch researchers in oncology and other key diseases, and we are glad that the CUHK group has chosen MetaCore. Disease area specific content is one of our important development goals for the next 3 years.” Download this press release in PDF format. THE SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE JOINS THE METAMINER CARDIAC CONSORTIUM St. Joseph, MI. April 15th, 2008 – GeneGo, Inc., the leading systems biology tools company, announced today that The Scripps Translational Science Institute have joined the MetaMiner Cardiac Consortium. The goal of the Consortium is to build the first systems biology and pathway analysis platform for cardiovascular diseases in the world. The Consortium members will vote on deliverables that will include disease specific pathway maps and networks built by experts in the field. GeneGo will also develop relevant ontologies for cardiovascular diseases and drugs. GeneGo’s VP of Business development. “The cardiovascular disease area is complex and a challenging field. We believe that MetaMiner Cardiac will have an impact on both basic research and drug discovery in this area.” Download this press release in PDF format. GENEGO ROLLS OUT METAMINER CYSTIC FIBROSIS -- THE FIRST DISEASE - SPECIFIC SOFTWARE PLATFORM TO ADVANCE DRUG DISCOVERY St. Joseph, MI. March 26th, 2008. GeneGo, Inc., the leading systems biology tools company, announced today the release of MetaMiner Cystic Fibrosis, a first of its kind software and database platform designed to help advance drug discovery for cystic fibrosis, a lifethreatening genetic disease. This novel, disease-specific tool will provide the cystic fibrosis research community with state-of-the art methods for integrating and analyzing cystic fibrosis data. Cystic Fibrosis Foundation Therapeutics, Inc., a non-profit affiliate of the Cystic Fibrosis Foundation, provided funding and guidance to the project with the GeneGo’s VP of Business Development. “We enjoyed working with the Foundation and the team of world-class experts they assembled for this project. In phase one, we built a database of all relevant small experiments information on the disease as well as over 30 cystic fibrosis specific pathway maps and networks. We believe this environment will help find a cure for cystic fibrosis faster as we move in to the next phase of the collaboration”. MetaMiner Cystic Fibrosis includes off-the-shelf GeneGo products -- MetaCore, MetaDrug and MapEditor -- as well as cystic fibrosis experiments content annotated by GeneGo in the form of disease maps, networks and a database of biomarkers and active compounds. A committee of researchers from the cystic fibrosis community guided the cystic fibrosis-specific annotation under the sponsorship of CFFT. MetaMiner Cystic Fibrosis provides researchers with the ability to interpret emerging data from global experiments, like arrays GeneGo’s VP of Business development. “We will continue to work closely developing new functionality, tools and content for GlaxoSmithKline.” Download this press release in PDF format. U.S. ARMY CENTER FOR ENVIRONMENTAL HEALTH RESEARCH LICENSES METACORE FOR BIOMARKER RESEARCH St. Joseph, Michigan, January 29th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the U.S. Army has extended their license of MetaCore. The US Army Center for Environmental Health Research will use MetaCore in its Biomarker Discovery Program to identify novel biomarkers for exposure to TICs/TIMs in order to provide enhanced health surveillance for military personnel. “We are pleased that institutes on the bleeding edge of technology such as the U.S. Army are using MetaCore in their research” said Julie Bryant, Vice President of Business Development at GeneGo. “Soldiers and other service members can be exposed to a large number VP of Business development for GeneGo. “Disease-centric systems medicine is a natural and logical step in the development of our tools and databases and we are excited to see healthcare organizations such as Finnish Red Cross using it in such practical and important way.” Download this press release in PDF format. GENEGO COLLABORATES WITH UNIVERSITY OF ILLINOIS AT URBANACHAMPAIGN TO INCLUDE BOVINE SPECIES INTO METACORE St. Joseph, Michigan, January 15th, 2008 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced they will include bovine orthologs in the next release of MetaCore, in collaboration with University of Illinois Urbana-Champaign whom identified the matching bovine-mouse-rat-human orthologous pairs. The latest version MetaCore 4.5 already includes mouse, rat, fly, worm, yeast, chicken, chimpanzee, Rhesus Macaque, dog, and Malaria plasmodium, making MetaCore the broadest platform available for non-human species research. MetaCore also has a unique rat and VP of Business Development. “We provide more species and unique interaction databases for mouse and rat that will grow as we continue to innovate.” Harris Lewin, Principal Investigator and Director of the Institute for Genomic Biology at UIUC had this to say”We were very pleased to work with the team at GeneGo on the identification of cattle orthologs. My group feels that MetaCore is currently the premier product for data mining and pathway analysis. The addition of bovine orthologs of human, mouse and rat genes to MetaCore will make the recently sequenced cattle genome more accessible for functional genomics and systems biology.” Download this press release in PDF format. UC BERKELEY EXPANDS MOLECULAR TOXICOLOGY CURRICULUM TO INCLUDE GENEGO'S PLATFORM St. Joseph, MI. January 8th 20th, 2008 – GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that UC Berkeley will expand Vice President of Business Development for GeneGo. “The study of fundamental biology is changing quickly with omics technology and systems level analysis, and these changes affect application fields such as toxicology. UC Berkeley will be educating a new breed of toxicology researchers that are needed for the future success of taking drugs to market.” “Today’s drug and chemical safety assessment process increasingly leverages information from many different sources,” said Dr. Richard Brennan, GeneGo’s Director of Toxicology. “Molecular toxicologists need to be able to put traditional toxicology measurements in the context of chemical information as well as biochemical, gene expression, protein and metabolite data. Industry needs scientists well-versed in complex systems biology data, and in the powerful and flexible analysis tools increasingly used in safety assessment. UC Berkeley is leading the way in providing training in current and emerging technologies, and we are pleased to be able to contribute Vice President of Business Development for GeneGo. “The Cytoscape project has grown into, probably, the most advanced and well known developer’s community in systems biology, and we are very glad to participate in it. We know that our tools and content will be of interest for Cytoscape users.” Download this press release in PDF format. TNO EXTENDS LICENSING AGREEMENT WITH GENEGO AGAIN St. Joseph, MI. December 4th, 2007 – GeneGo, Inc., the leading systems biology tools company, announced today that TNO, The European Nutrigenomics Organisation (NUGO) Consortium and The Netherlands Nutrigenomics Consortium (NGC) have extended their agreement with Genego. Further, the recently established Netherlands Toxicogenomics Centre (NTC) will soon acquire MetaCore and MetaDrug for applications in toxicogenomics. This provides over 20 universities in Europe with access to MetaCore. GeneGo has a unique Rodent version of MetaCore with rat and mouse genes, protein complexes and interactions. This is GeneGo’s VP of Business development. “The projects we collaborate on include a study on cholesterol diet and drug effects on atherosclerosis and nutrigenomics. TNO is also using GeneGo products as part of their tox service offerings. We look forward to further collaborations and more publications.” Download this press release in PDF format. ELAN PHARMACEUTICALS JOINS GENEGO'S METATOX CONSORTIUM St. Joseph, MI. November 27th, 2007 — GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Elan Pharmaceuticals has joined the MetaTox Consortium. The Consortium, led by Dr. Richard Brennan, will be focused on developing systems biology tools for safety assessment of small molecule compounds and biological therapeutics. This effort will include expanding the existing tools in the MetaDiscovery™ platform with toxicity ontologies, developing “knowledge-based” predictive models (functional descriptors), manual reconstruction of toxicity pathways in human and relevant preclinical model species, and the Vice President of Business Development for GeneGo. “The Consortium will propose the deliverables, to be voted on and prioritized by the members, and GeneGo will then develop and deliver the agreed-upon content and software with members’ input. All the members joining to date have said that they could not perform this amount of work internally for the membership fee, which helped to justify the business model.” “Despite the increasing deployment of new technologies probing the molecular basis of chemical toxicity, too many investigational drugs still fail in clinical trials due to human toxicity unseen in pre-clinical safety assessment”, said Dr. Richard Brennan, Director of Toxicology at GeneGo, “The Consortium, which includes representatives from industry and from FDA , believes that part of the problem lies in a lack of appropriate data analysis tools to properly integrate the multiple data types generated by data-rich ‘omics technologies, and to convert findings Vice President of Business Development for GeneGo. “Academia pushes the limits of MetaDrug™ which allows us to further adapt it for new areas of medicinal chemistry and they publish new applications that we may not even have thought of using it in such a way.” Download this press release in PDF format. ELAN PHARMACEUTICALS, INC. LICENSES SOFTWARE AND DATABASES FROM GENEGO St. Joseph, MI. October 30th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Elan Pharmaceuticals, Inc. licensed its flagship data analysis suite MetaCore™. The platform will be available to all scientists in research. MetaCore™ is designed for functional analysis of biological and chemistry data. Elan will use MetaCore™ in their neurology and autoimmune programs. “We are very pleased that Elan chose GeneGo and we have had good interactions so far,” said Julie Bryant, GeneGo’s VP of Business development. “MetaCore™ has substantial knowledge content Vice President of GeneGo. “AVEO’s vision and focus in cancer drug research and development is inspiring and we believe our MetaCore™ suite of data mining tools will be an asset to their efforts.” Download this press release in PDF format. ORGANON EXTENDS METACORE™ LICENSE AND ADDS METALINK™ St. Joseph, MI. October 2nd, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Organon, the human health care business unit of Akzo Nobel, have extended their GeneGo software and database licenses. In addition to extending their MetaCore™ license, Organon has also added MetaLink™ so that they can upload their own interaction data and visualize it in the context of MetaCore’s manually curated content. GeneGo offers easy to use automated workflows that casual users can use and these are now also available through their new product 1-2-3 workflow™ which is a “pay as you go” business model. GeneGo GeneGo’s VP of Business Development. “We have received good development feedback from Organon over the years and implemented many of their ideas in MetaCore™”. Download this press release in PDF format. GENEGO ENTERS MULTI-YEAR AGREEMENT WITH BRISTOL MYERS SQUIBB FOR ACCESS TO GENEGO SOFTWARE SUITE AND DATABASES St. Joseph, MI. September 25th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Bristol-Myers Squibb (NYSE: BMY) has licensed access to all major GeneGo products. Using the licensed GeneGo technology, research and development sites within Bristol-Myers Squibb will have the ability to start with chemical compound structures and/or genomics data to address questions from both chemistry and biology domains. Bristol-Myers Squibb can also access GeneGo tools to build their own canonical pathway maps using public, GeneGo, and proprietary data and have those maps included in statistical calculations and overlays. In addition, Bristol Myers Squibb researchers can leverage GeneGo’s VP of Business Development. “We plan to continue this collaborative spirit over the next few years.” Download this press release in PDF format. GENEGO AND THE CYSTIC FIBROSIS FOUNDATION COLLABORATE TO ADVANCE UNDERSTANDING OF CYSTIC FIBROSIS St. Joseph, MI. September 11th, 2007 — GeneGo, Inc. and the Cystic Fibrosis Foundation announced today their collaboration to develop a software suite for the integration and analysis of cystic fibrosis data. GeneGo’s proprietary software combines analytical tools, data content and algorithms for understanding the complex interconnected pathways that are affected in common human diseases. “We hope this collaboration will better help us to understand the disease and potential therapies at the molecular level,” said Robert J. Beall, Ph.D., president and CEO of the Foundation. “Using computational platforms adds to our arsenal of already existing strategies.” The new platform, called MetaMiner™ (CF), will include off-the-shelf GeneGo products such as MetaCore™, MetaDrug™, MetaLink™ GeneGo’s vice president of business development. “This collaboration is the first in the series of diseasecentered MetaMiner™ projects which integrate our existing data analysis tools, OMICs data warehousing and disease-specific knowledge base. We have a dedicated group of Ph.D. and M.D. scientists to work on this project.” The project will be guided by a Cystic Fibrosis Foundation committee with a goal to leverage systems biology technology and accumulated data to advance drug discovery for this disease. MetaMiner™ (CF) is expected to be available by February of 2008 to cystic fibrosis academic researchers and drug development collaborators through access licenses. Cystic fibrosis is a genetic disease that affects about 30,000 adults and children in the United States. It causes life-threatening lung infections and serious digestive complications. More than 10 million Americans are symptomless carriers of the CF gene. About the Cystic Fibrosis Foundation The Cystic Fibrosis Foundation is the leading GeneGo’s VP of Business Development. “Over the years, their valuable feedback has helped GeneGo to develop new features and products, and we look forward to expanding relationships with their labs”. Download this press release in PDF format. GENEGO ANNOUNCES LICENSING AGREEMENT WITH BIOGEN IDEC St. Joseph, MI. August 28th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Biogen Idec (NASDAQ: BIIB) licensed its data analysis suite, MetaCore. Biogen Idec researchers can study their proprietary experimental data in the context of seven functional ontologies and unique merged metabolic/signaling networks. Importantly, MetaCore manually curated content now covers 12 organisms, and enables concurrent analysis of virtually any type of OMICs data including SNPs, MPSS files, microarray gene expression, proteomics, metabolomics and custom interactions. “Biogen Idec is such a great success story and we are pleased to help them in future achievements,” said Julie Bryant, GeneGo’s VP of GeneGo’s VP of Business Development. “We have seen a surge of diagnostic companies, such as Almac Diagnostics becoming GeneGo customers over the last couple of years, and Philips is the latest addition. We welcome the expansion of the scope of systems biology applications beyond drug discovery.” Download this press release in PDF format. THE INSTITUTE FOR SYSTEMS BIOLOGY LICENSES METACORE™ FROM GENEGO St. Joseph, MI. July 24th 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that The Institute for Systems Biology (ISB) has licensed its OMICs data analysis suite, MetaCore™ and 1-2-3 Workflow. All ISB researchers will have access to GeneGo pathway analysis and systems biology tools. MetaCore will be integrated with Cytoscape, an open source network visualization software supported by ISB. GeneGo and ISB also plan to collaborate on several research projects. ISB is an internationally renowned, non-profit research institute headquartered in Seattle and GeneGo’s VP of Business Development. “ISB, led by Dr. Lee Hood, is the premium academic institution in our field, with outstanding research and vision. We are looking forward to working with them in systems biology of human diseases.” Download this press release in PDF format. EXPRESSION ANALYSIS ENTERS AGREEMENT WITH GENEGO TO PROVIDE FUNCTIONAL ANALYSIS SERVICES USING 1-2-3 WORKFLOW™ St. Joseph, MI. July 10th 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that Expression Analysis, Inc. will be providing functional analysis (pathways and networks) add-on services to their customers. Expression Analysis is the leading microarray services and solutions provider for clinical trials customers. GeneGo’s “1-2-3 Workflow™” automatically uploads and normalizes genomics data, compares multiple expression datasets to identify their common, similar and unique components, conducts enrichment analysis in multiple knowledge ontologies such as diseases, canonical pathways and functional processes and then calculates the most GeneGo’s VP of Business Development.“1-2-3 Workflow™ is an ideal vehicle for value-add functional analysis for OMICs service organizations as it provides a very comprehensive report quickly and in an easy-to-understand Word format at a reasonable cost.” “Expression Analysis is committed to being a full-service genomics provider,” said Steve McPhail, CEO and President of Expression Analysis, Inc. “Our standard microarray service includes statistical analyses to identify differentially expressed genes. However, some investigators request help translating the gene list into functional relationships. The GeneGo service will provide this assistance using an established software product. We see it as a natural partnership for both companies and a definite value for our clients.” About Expression Analysis, Inc.: Expression Analysis, Inc. ( http://www.expressionanalysis.com ) is the industry's leading provider of microarray-based genomic services for clinical trials. Specializing in gene expression and genotyping assays on Affymetrix GeneChip microarrays, the company also provides complementary services using GeneGo’s VP of Business Development. “Our goal in development of 1-2-3 Workflow™ was to adapt our functional data analysis technology for occasional users, which means automation and ease of use without a compromise on quality. We believe that Monarch LifeSciences’ customers will be very happy with the analysis provided.” “Our goal is to provide our customers with reliable proteomics data that can easily integrate into their research programs,” said Lauri Caviston, Monarch LifeSciences’ VP of Business Development. “GeneGo provides an excellent tool for taking the data we generate to the next level.” About Monarch LifeSciences: Monarch LifeSciences provides services in protein biomarker discovery, development and validation for the pharmaceutical and biotech industries. Monarch’s biomarker discovery services include experimental design, proprietary sample preparation methods and quantification algorithms to ensure the generation of quality data. The LifeMarker™ Assay supports both pre-clinical and clinical applications of biomarkers and provides accurate high throughput VP of business development. “Metabolic data is hugely important in diagnostics and drug discovery, as any major disease fundamentally affects core biochemical pathways. Yet, MetaCore/MetaDrug is the only product in the field which enables direct parsing, pathway and network analysis of human metabolic data and its integration with genomics, proteomics and genetic data. Now, our customers will have this functionality accessed directly from Chenomx software”. About Chenomx, Inc. Chenomx, Inc. is a privately-held Canadian company that specializes in the development of complex mixture analysis software for broad application in life science technologies. With world-class expertise in NMR spectroscopy, pharmaceutical sciences, and computer software, Chenomx offers a broad range of software products and compound databases to support the metabolomics communities’ research efforts. Chenomx’s flagship product, Chenomx NMR Suite, provides a rich set of tools for identifying and quantifying metabolites in complex NMR Spectra. More information on Chenomx and its solutions Vice President Business Development , GeneGo commented: “We are very pleased to work with GVK BIO. GeneGo, like our end users, drug companies, have to make “build versus buy” decisions, but it is difficult to find content that fits our high quality criteria and adds value to the databases we have already assembled. This is the first time we have accepted any third party content”. Informatics at GVK BIO The Informatics division is responsible for analyzing data to transform chemical / biological patterns into knowledge. Informatics offers Custom Curation, Cheminformatics and Bioinformatics services to global clients. It also licenses and sells databases to Biotech and Pharma companies. GVK BIO’s clients include 15 of the top 20 Pharmaceutical companies. About GVK BIO GVK Biosciences is one of Indias premier Contract Research Organizations, providing an integrated platform of research services across the Pharma R&D value chain to a growing number of GeneGo’s VP of Business Development. “We also think that the end users, wet lab scientists, see biologically relevant results using MetaCore™ that they are not getting from other tools.” Download this press release in PDF format. GENEGO WINS FROST & SULLIVAN AWARD FOR BIOINFORMATICS OURSOURCING AND COMPETITIVE STRATEGY YIELDING SIGNIFICANT COMPETITIVE MARKET GAINS St. Joseph, MI. March 13th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that they have been awarded a 2006 competitive strategy and bioinformatics outsourcing leadership award from Frost & Sullivan, competing with 150 other companies in Life sciences. Frost & Sullivan cited that GeneGo’s innovative competitive strategy had yielded significant market gains and their analysts expect such innovations will produce lasting, precedent setting trends. This information was gathered by interviews with the experts in the field, end users and the companies themselves. Frost & Sullivan also state that GeneGo is GeneGo’s VP of Business development. “We would also like to acknowledge help and support from our customers and partners whose feedback is really important in our product development.” To download the white paper please click here . Download this press release in PDF format. GENEGO’S METADRUG™ WON THE BEST IN SHOW NEW PRODUCT AWARD AT THE 2007 MOLECULAR MEDICINE MEETING St. Joseph, MI. March 7th, 2007 — GeneGo, Inc., the leading systems biology tools company, announced today that its systems pharmacology product MetaDrug 2.0™ won the “Best in Show” product award at the CHI’s Molecular Medicine Marketplace (MMM) conference held in San Francisco last week. MetaDrug™ was chosen a winner among six other systems biology products by conference attendee votes. MetaDrug™ helps to predict indications, off target effects and human toxicity for novel small molecules compounds using systems level chemoinformatics tools and manually annotated knowledge base of compound-target GeneGo’s VP of Business development. “MMM is the most important trade show in our field and is attended by the top experts in systems biology, translational medicine and medicinal chemistry, whose opinion matters a great deal for us. This year, we took a considerable risk with MetaDrug™, our second product, as it competed with the latest versions of flagship suites launched by our competitors at MMM. We are glad this risk paid off”. “MetaDrug™ is a unique platform”, said Tatiana Nikolskaya, GeneGo’s CSO and President. “There are probably a hundred commercial and open source products for pathway and network analysis of biological data but virtually nothing for chemistry. Prediction of biological effects for small molecules is a tough problem. Structure-centered chemoinformatics tools do not help explain systems level effects like disease indications; and simple assembly of ligand-receptor interactions databases are not sufficient either. We spent almost three years developing GeneGo’s VP of Business Development. “We developed it based on many requests from our “Google-generation” customers who want the basic analysis done “within 30 minutes with one click”. The trick was to combine the “ease of use” functionality with high quality analysis GeneGo is known for and sophistication of algorithms necessary for analysis of genome-wide datasets accessing the highest quality content in MetaCore™” “1-2-3 Workflow™ is not about stripping-down functions of our larger product, MetaCore™&rdqou;, says Tatiana Nikolskaya, GeneGo’s President and CSO.“You can consider it as a “condensed wisdom” of our data mining projects run in house in several disease areas and toxicity for several years. We wrapped this knowledge and “know how” up into a workflow with several knowledge ontologies for enrichment analysis, the most advanced network building algorithms we have and our experience in finding the most relevant biomarkers and targets”. Download this press release in PDF Vice President of Business Development at GeneGo. “GeneGo has an open partnering philosophy and we always look forward for expansion of our product integration space. We are very pleased with the current project with Spotfire, the dominant player in the data analysis market.” About Spotfire Spotfire, the Information Insight CompanySM, is a leading provider of enterprise analytics software that helps professionals quickly discover new and actionable insights in information. For thousands of business professionals faced with day-to-day decisions, Spotfire offers a visual and interactive analytics experience that helps them make decisions with speed and confidence. Distinguished by its ease of use and analytic power, Spotfire software rapidly reveals unseen threats and illuminates new opportunities, creating significant economic value. Spotfire’s customers include industry leaders among the Global 2000 that have deployed Spotfire analytics to gain an information advantage over their competitors. For more information, visit www.spotfire.com . Spotfire, DecisionSite Vice President of Business Development at GeneGo. “Our products are gaining momentum in clinical diagnostics, both on the development side and among practitioners. Almac combines both as a highly reputable, scientific oriented new generation CRO.” About Almac Diagnostics Almac Diagnostics develops, markets and supplies, leading edge genomic products and services. It is a member of the Almac Group, an organization providing services from R&D through clinical development to manufacture of pharmaceutical product. Almac Diagnostics has two divisions: The Genomic Services division provides all inclusive gene expression, SNP and bioinformatics services to academia, biotech and pharmaceutical companies. These services include analysis on our unique DSA™ research tools, which provide the ability to detect the maximum information in a given cancer type. Almac Diagnostics is the first Authorized Affymetrix Service Provider to successfully gain accreditation to ISO17025 for our comprehensive Gene Expression Microarray and Bioinformatics services. The Research Vice President of Business Development at GeneGo. “The new products round up our customization suite of tools which also includes PathwayEditor, launched two years ago. With these additions, the MetaCore™ platform has become a truly universal environment for functional data mining, capable of handling analysis of any type of molecular omics data and gene/protein association data. The main functional blocks in MetaCore™, canonical maps and networks are now completely editable, seamlessly integrated and internally consistent.” Download this press release in PDF format. DOW NEUROBIOLOGY LABROATORIES EXTENDS THEIR METACORE™ LICENSES FROM GENEGO St. Joseph, Michigan, October 17th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Robert S. Dow Neurobiology Laboratories extended their MetaCore™ license. Scientists in RSDNL have been using MetaCore™ for analysis of proteomics and gene expression data for understanding ischemic brain injury and its prevention. MetaCore™ is an Vice President of Business Development at GeneGo. “Comparing multiple data types is essential; equally important is to depict pathways and networks for biologically meaningful data integration.” Download this press release in PDF format. GENEGO INC. IS AWARDED PHASE II NCI GRANT FOR NETWORK BIOMARKERS IN BREAST CANCER St. Joseph, Michigan, October 3rd, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis, announced today that they have been awarded a Phase II SBIR grant from the National Cancer Institute for discovery of new biomarkers implicated in breast cancer based on network analysis. The research program includes a novel large scale gene expression and genotyping study to be run at Mayo Clinic and data analysis in MetaCore™, GeneGo’s flagship data mining platform. “We are very happy to receive this Phase II award from NCI in the current highly competitive environment as Vice President of Business Development at GeneGo. “Now, more groups at Merck KGaA will be able to use MetaCore™ in both early discovery and new compound safety testing.” Download this press release in PDF format. WASHINGTON STATE UNIVERSITY EXTENDS METACORE™ LICENSES FROM GENEGO St. Joseph, Michigan, September 19th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Washington State University Tri-cities has extended their license of MetaCore™. MetaCore™’s new release 4.0 has unique features that give researchers a multi-level analysis of experimental data with respect to functional processes, diseases and consensus pathways in just one click. “We have been loyal MetaCore™ users for quite some time now and we have been able to make significant progress in our projects supported by the Department of Energy’s Low Dose Radiation Research Program. The software helped us to interpret proteomic data from Vice President of Business Development at GeneGo. “Academic scientists are a fast growing and invaluable customer base for GeneGo. We like working with academics because of the high quality of research and challenging yet constructive feedback. GeneGo is known as the innovator in functional analysis, and many of our development ideas come from academic collaborations and requests.” Download this press release in PDF format. NIDDK RENEWS METACORE™ LICENSE AND COLLABORATES WITH GENEGO IN DIABETES RESEARCH St. Joseph, Michigan, August 15th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis announced today that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH), has renewed its MetaCore™ license from GeneGo to continue a research collaboration with GeneGo on functional analysis of insulin-resistant diabetes in human and animal models. Diabetes, obesity, and other Vice President of Business Development at GeneGo. “Over the last year, systems analysis of biological data has become mainstream, rather than a niche application, for high volume high throughput genomics labs. The new customization tools and expansion of knowledge content in disease areas make MetaCore™ applicable for focused research programs at specialized drug discovery companies. We are proud that Galapagos has selected MetaCore™ in the competitive market of pathways tools.” Download this press release in PDF format. GENEGO AND ELSEVIER MDL COLLABORATE TO PROVIDE SEAMLESS ACCESS TO COMPOUND DATABASES, PATENTS, LITERATURE AND PATHWAYS St. Joseph, Michigan, July 20th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology and pathway analysis and Elsevier MDL, a leading provider of scientific content, informatics framework and workflow applications for pharmaceutical research, announced the collaboration. The latest version of GeneGo’s data mining platform MetaCore™ 4.0 will be VP Business development at GeneGo. “Although pathways and network analysis of bioactive compounds is a common practice in MetaCore™, we partnered with Elsevier MDL for in depth coverage of literature and patentderived information relevant for compounds. We are very pleased to be working with Elsevier MDL, the market leader in medicinal chemistry knowledge databases, Integration with the Elsevier MDL chemistry space opens up new applications for our products in medicinal chemistry, including high-throughput and high-content screening, hit selection and validation, lead development programs and chemogenomics.” About Elsevier MDL Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists' decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com . Elsevier Vice President of Business Development at GeneGo. “MetaCore™ has been applied extensively in the area of reproductive medicine by several pharmaceutical companies and academic groups, but this is the first time it will be used by health care practitioners. This is very encouraging as our ultimate goal is to adapt systems data analysis technology to the needs of doctors and individual patients.” Download this press release in PDF format. SIENA BIOTECH EXPANDS METACORE™ LICENSE FROM GENEGO St. Joseph, Michigan, July 5th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Siena Biotech has expanded the number of MetaCore™ licenses obtained from GeneGo. MetaCore™’s technology platform’s capacity to integrate multiple data types including proteomics and chemogenomics data was valued by Siena Biotech together with the quality of content in neurological diseases. “We appreciate MetaCore™’s flexibility and GeneGo’s ability to quickly Vice President of Business Development at GeneGo. “We are seeing more of our customers expanding the scope of data types analyzed in MetaCore™ in their R&D efforts. MetaCore™ is well equipped for this with its capacity to concurrently visualize, score and process gene expression, proteomic, metabolomic and compound data.” Download this press release in PDF format. NHLBI EXPANDS THEIR METACORE™ LICENSE TO COVER NHLBI, CORE, CIT AND CRITICAL CARE MEDICINE DEPARTMENT St. Joseph, Michigan, June 27th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that their multi year agreement with NHLBI will be extended and expanded to cover National Heart, Lung and Blood Institute core microarray group, the Center for Information Technology and the Critical Care Medicine Department of the NIH Clinical Center. MetaCore™ will also be used throughout their new systems biology group and it will be an Vice President of Business Development at GeneGo. “The field of functional data mining is evolving very rapidly, and collaborations with the leading academic institutions help us to be on top of state of art technology. MetaCore™ is a very dynamic platform, and the feedback from collaborators is essential in its development.” Download this press release in PDF format. BOEHRINGER INGELHEIM LICENSES METACORE™ FROM GENEGO FOR TOXICOGENOMICS STUDIES St. Joseph, Michigan, June 20th, 2006 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Boehringer Ingelheim has licensed its data mining suite, MetaCore™, primarily for toxicogenomics research. MetaCore™ is based on a comprehensive, manually curated database of human biology, diseases, toxicology and bioactive chemistry. “Toxicogenomics is one of the main applications of MetaCore™, and we pay a lot of attention to the field in product development.” said Julie Bryant, Vice President of Business vice president of Business Development at GeneGo. “GeneGo has an open, market-driven partnering philosophy, and we are happy that Agilent has a similar viewpoint. We look forward to receiving more customer feedback and further developing our systems’ interoperability.” “The use of informatics to enable life science research has changed dramatically in the last 18 months,” said Jordan Stockton, Agilent Informatics marketing manager. “Today, researchers demand applications that allow them to pool evidence from as many sources as possible. The integration of GeneSpring and MetaCore allows leading scientists to rapidly synthesize information about pathways and molecular interactions with those from microarray technologies.” Download this press release in PDF format. PEAKADILLY LICENSES METACORE™ FROM GENEGO St. Joseph, Michigan, May 15th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Peakadilly NV, Belgium, has licensed MetaCore™ for use in proteomics research. MetaCore™ Vice President of Business Development at GeneGo. "Compared to genomics, proteomics data is more complex, yet they provide unique insights about active cell machinery. Proteomics data mining is an important area in our technology development and one for which we have been awarded government grants." About Peakadilly Peakadilly was founded in late 2004 to exploit the protein biomarker discovery technology developed at VIB and the University of Ghent. In this short time, it has successfully implemented the technology and won revenue generating projects with big pharma. It applies the technology both to third party projects and to its own projects for developing a new generation of diagnostics and pharmacodiagnostic products. Download this press release in PDF format. GENEGO AND XB TRANSMED SOLUTIONS PROVIDE INTEGRATED SOLUTIONS TO THE TRANSLATIONAL MEDICINE MARKET St. Joseph, Michigan, April 24th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems Vice President of Business Development at GeneGo. "Understanding the differences of drug effects on individual patients is a very challenging task, which requires state of the art tools in both translational medicine and functional data mining. We are very pleased to join forces with XenoBase inventors Dr Craig Webb and Dr. Jeremy Miller at the Van Andel Institute to develop analytical workflows for the clinical environment." About XB TransMed Solutions XB TransMed Solutions, was founded as a next generation life science application and services company with headquarters in Grand Rapids, Michigan. The focus of XB TransMed Solutions is to provide leading edge software and service solutions expediting the complete life science work process from novel discovery to clinical application in an integrated environment. XB Trans Med markets its Bio-Integration Suite as a fully integrated biological and medical informatics solution that allows users to generate, refine, and validate causal hypotheses Vice President of Business Development of GeneGo. "InforSense workflows enable life science researchers to compose and execute scientific analyses quickly and easily without programming, sharing both methods and results with co-workers." "MetaCore has grown to become a key component in the research toolbox in the life sciences, particularly within the pharmaceutical industry, and we are pleased to have the opportunity to work with GeneGo," commented Dr. Jonathan Sheldon, Chief Scientific Officer, InforSense. "The integration of pathway analysis with InforSense KDE is a key component of our multidisciplinary analytics platform for Systems Biology." About InforSense InforSense Ltd., the leader in integrative analytics, enables organizations to orchestrate and optimize their business-critical decision-making processes. Leading pharmaceutical and biotechnology, consumer goods, financial services companies, and research institutes are using the company's flagship product, InforSense KDE, to enhance productivity across life science R&D, healthcare, and business analytics. The company is privately held, with European Vice President of Business Development at GeneGo. "Berlex researchers will be among more than 140 unique accounts and thousands of users. Feedback from such partnerships help us enhance MetaCore™ as a versatile, multi-purpose data mining tool applicable in diverse life science projects. Download this press release in PDF format. GENEGO EXPANDS LICENSE WITH JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT TO INCLUDE METABASE™ ACCESS St. Joseph, Michigan, February 20th, 2006 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Johnson & Johnson Pharmaceutical Research & Development, (J&JPRD), a division of Janssen Pharmaceutica N.V., has extended their MetaCore™ license to now include MetaBase™, a database J&JPRD will primarily use for biomarker discovery. "We are pleased to have this relationship extended," said Julie Bryant, Vice President of Business Development at GeneGo. "We look forward to enhancing our collaboration with the MetaBase™ integration." Download Vice President of Business Development at GeneGo Inc. GeneGo's flagship analytical suite, MetaCore™ combines a manually curated database of clinical and pre-clinical biology information and bioactive compounds with comprehensive pathways and network analyses. Bryant added, "MetaCore™ can now be connected with Genedata Expressionist® and Genedata Phylosopher®, so mutual customers will be able to move iteratively between the software systems seamlessly and inter-operatively". "Genedata's open and scalable architecture provides a strong basis for integration with client and third party content", says Dr. Daniel Keesman, CEO of Genedata AG. Expressionist enables omics data and associated information to be imported, processed and analyzed in an automated and repeatable workflow. Phylosopher has been integrated closely with MetaCore's visualization tools to identify and prioritize pathways affected by disease. The integrated solution achieves unrivaled standards in research information management and decision support. Dr. Keesman added, "This integration has been customer-led and helps scientists place their VP business development. "The field of functional data analysis is maturing rapidly, and it is crucial for us to work closely with state-of-art research teams, such as those at Merck." Download this press release in PDF format. SCITEGIC'S ISV PARTNER PROGRAM WELCOMES TWENTIETH MEMBER SAN DIEGO, CA, January 9, 2006 - SciTegic , the leader in data pipelining and workflow tools announced today that four new members have joined its Independent Software Vendor (ISV) partner program. The program's aim is to compile a collection of high value life sciences applications to address customer needs for increased software interoperability. Through new collaborations with ACD/Labs, Bio-Rad, GeneGo, and Partek, scientists in drug discovery will obtain access to new, integrated software products that will help them solve more complex research problems in a more efficient manner. "We are pleased to see a rapidly growing community adopt the Pipeline Pilot platform for life Vice President of Business Development of GeneGo. "Joint customers will be able to increase their research efficiency by rapidly incorporating pathway information in their workflows." "We are pleased to join SciTegic's ISV program," said Tom Downey, President and CEO of Partek, "as it allows us to bring together the data workflow capabilities of Pipeline Pilot with the statistics and interactive visualization capabilities that our software offers, allowing life sciences researchers to make better decisions." Download this press release in PDF format. TNO EXPANDS RELATIONSHIP WITH GENEGO TO COVER ALL MAJOR EUROPEAN NUTRIGENOMICS INITIATIVES St. Joseph, Michigan, November 14th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, announced today the expansion of their partnership with TNO (the worlds largest independent nutrition research institute, www.tno.nl), the Dutch Nutrigenomics Consortium and the European Nutrigenomics Organization (NUGO, www.nugo.org), together forming a group of 23 Universities and VP of business development at GeneGo. "Our collaboration with TNO researchers helped us to adjust MetaCore™ for the needs of nutritional science which requires comprehensive coverage of human metabolism and understanding the connectivity between metabolic and signaling pathways. We have also developed the first metabolic parser which enables import of metabolomics data, its visualization and analysis along with molecular data in the framework of pathways and networks." Download this press release in PDF format. VELCURA THERAPEUTICS AND GENEGO ENTER MULTI YEAR AGREEMENT St. Joseph, Michigan, November 9th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Velcura Therapeutics, Inc. has licensed MetaCore™, GeneGo's manually curated pathways database and data mining suite. All Velcura employees will have access to the MetaCore™ database and suite of software tools for three years to focus on bone related disease research. Velcura researchers will be Vice President of Business Development at GeneGo. "High-throughput experimentation matures fast, and nowadays researchers deal not only with gene expression, but also individual DNA variability, protein abundance and isoforms content, changes in body liquid metabolic profiles and high content drug screening data. To be able to visualize and analyze such diverse datasets, we have built a comprehensive database of direct interactions between genes, proteins, enzymes, metabolic by-products and cell-regulators in human and other mammals. Velcura researchers will be able to directly access this content and use it in projects via their MetaCore™ license." Download this press release in PDF format. FOR THE FIRST TIME, SIGNALING AND METABOLIC NETWORKS CAN NOW BE MERGED WITH GENEGO'S METACORE™ VERSION 3.0 St. Joseph, Michigan, October 31st, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, announced today the major new release of its flagship data mining platform VP of business development at GeneGo. "Think about cross-validation of metabolic biomarkers and drug mode of action studied in animal systems and screening data. MetaCore™ 3.0 is a common environment for both biologists and chemists throughout the whole drug discovery pipeline. We have also addressed sharing of experiments, knowledge and analysis with a sophisticated enterprise account and experiment management system with hierarchical access to shared accounts, data and results exchange and annotation through e-notes." Download this press release in PDF format. THE U.S. FOOD AND DRUG ADMINISTRATION WILL USE GENEGO'S METACORE™ FOR "OMIC'S" RESEARCH AND REVIEWING OF GENOMICS DATA St. Joseph, Michigan, October 10th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the U.S. Food and Drug Administration (FDA) have licensed MetaCore™ for "OMIC's" research and reviewing of genomics data. GeneGo and the FDA will also integrate MetaCore™ with Vice President of Business Development at GeneGo. "Since MetaCore™ is already being applied in drug discovery by our pharmaceutical customers for a couple of years now, it is logical that it will be also used on the regulatory side as well." GeneGo has assembled the world largest manually curated database of human biology and medicinal chemistry, which includes genes, proteins, natural ligands, metabolites, drugs and diseasesfrom millions of literature findings. About Array Track ArrayTrack provides an integrated solution for managing, analyzing, and interpreting microarray gene expression data. Specifically, ArrayTrack is MIAME (Minimum Information About A Microarray Experiment) supportive for storing both microarray data and experiment parameters associated with a pharmaco- or toxico- genomics study. Many statistical and visualization tools are available with ArrayTrack. ArrayTrack also provides a rich collection of functional information about genes, proteins and pathways for biological interpretation. The primary emphasis of ArrayTrack is the direct linking Vice President of Business Development. "We work in close contact with the Affymetrix team to keep on top of their development and new products". "Pathway analysis and annotation represents a critical link between microarray data and biomedical utility." Said Steve Lincoln, Vice President of Informatics at Affymetrix. "We are pleased to be working with GeneGo in integrating our platforms, allowing our mutual customers to get the most from their GeneChip data." Download this press release in PDF format. GENEGO IS AWARDED A PHASE II NIH GRANT FOR IN SILICO ASSESSMENT OF DRUG METABOLISM AND TOXICITY St Joseph, Michigan, August 8th, 2005 - GeneGo Inc., a leading provider of databases, software and services in systems biology, announced today that they have received a Phase II SBIR grant from the National Institute of General Medical Science. The grant enables the further development of a computational tool MetaDrug™ to improve the Vice President, business development. "Our customers particularly like the flexibility of the system which makes their version of MetaDrug™ specific to their chemistry space and informatics environment. We will continue working in this direction. New funding will also allow us to expand applicability of MetaDrug™ in other areas of biological effects of drug action such as pharmacogenomics, prediction of side effects and new therapeutic indications." "This funding will enable us to expand the scope of MetaDrug™ integrating predictive algorithms for ADME/Tox properties, and add a database of ligand-protein interactions from other species, in addition to humans," said Dr. Sean Ekins, Vice President of Computational Biology, GeneGo. "We will develop large in vitro datasets for drug interactions with key human cytochrome P450s that will be used to build predictive algorithms to complement those currently in MetaDrug™. We also intend to integrate a novel algorithm for metabolite prediction that will allow VP of Business Development. "We are hoping that the added visibility, especially at the core facility, will give more scientists a chance to utilize MetaCore™ in their research. We plan to continue to work closely with UCSD on these and several other projects." Download this press release in PDF format. ROSETTA BIOSOFTWARE AND GENEGO TO OFFER INTEROPERABILITY BETWEEN THE ROSETTA RESOLVER® SYSTEM AND METACORE™ SEATTLE, Wash., and ST. JOSEPH, Mich., July 18, 2005 - Rosetta Biosoftware and GeneGo, Inc. today announced a collaboration to establish interoperability between Rosetta Biosoftware's Resolver system and GeneGo's MetaCore™ system. Researchers will be able to easily exchange data between the MetaCore™ and Resolver systems to leverage both systems' ability to analyze gene expression data and perform sophisticated pathway analysis. The Rosetta Resolver system is a versatile and robust comprehensive gene expression data analysis system that enables research organizations to efficiently and effectively conduct vice president of business development. The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies. Download this press release in PDF format. SIENABIOTECH LICENSES METACORE™ FROM GENEGO St. Joseph, Michigan, July 6th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Siena Biotech has licensed MetaCore™ version 2.5, GeneGo's platform for mining and visualization of high-throughput experimental data in the context of biological networks, pathways and diseases. MetaCore™ enables concurrent visualization and analysis of gene expression, proteomics and metabolomics data in multiple formats including LocusLink, Genbank, RefSeq, All Affymetrix arrays tags, OMIM, Unigene, SwissProt as well as other approved gene symbol IDs. MetaCore™'s content is manually assembled from full text experimental articles by qualified curators. The latest release, MetaCore™ version 2.5, features multiple functions for statistical analysis of biological networks, inter-experimental comparisons, VP of Business Development. "With fast evolution of OMICs technologies, and concurrent analysis and cross-validation of multiple data types becoming increasingly important, we emphasize such features in the new version of MetaCore™. Sienabiotech will be able to visualize and directly compare gene expression and proteomic data on the same networks and pathways maps. Our new version features over 400 static maps of canonical signaling and metabolic pathways and eight network building algorithms." Download this press release in PDF format. GENEGO IS AWARDED DOD GRANT FOR SYSTEMS BIOLOGY PROTEOMICS PLATFORM St. Joseph, Michigan, June 27th, 2005 - GeneGo, Inc., a leading provider of databases, software and services in systems biology, announced today they have been awarded a SBIR grant from Department of Defense (DARPA) for the development of a systems biology suite of tools for visualization and analysis of proteomics data. In Phase I, GeneGo will adapt its data-mining VP of Business Development. "Cancer datasets are inherently complex for interpretation because multiple pathways and cell types are affected. Therefore, the requirements for data mining techniques and tools in oncology are high. We are very pleased that NCI scientists chose MetaCore™ as an enterprise, institution-wide system". Download this press release in PDF format. GENEGO IS AWARDED NIEHS GRANT IN TOXICOGENOMICS St. Joseph, Michigan, May 24th, 2005 - GeneGo, Inc., a leading provider of databases, software and services in systems biology, announced today they have received a Phase I SBIR grant from the National Institute of Environmental Health Sciences for the elucidation and analysis of signaling and metabolic networks implicated in cellular response to drugs and toxins. In the first phase of research, publicly available data will be re-analyzed by GeneGo scientists using the company's flagship systems biology platform, MetaCore™. "Over the past few years, we have witnessed an VP of business development at GeneGo. "TGen has amassed an impressive group of experts in pre-clinical research and clinical trials that we plan to collaborate with." About TGen The Translational Genomics Research Institute (TGen) is a not-for-profit organization whose primary mission is to make and translate genomic discoveries into advances in human health. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project to apply to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. Download this press release in PDF format. GENEGO LICENSES METACORE™ TO EXELIXIS St. Joseph, Michigan, May 13th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Exelixis has licensed MetaCore™, GeneGo's platform for mining of high-throughput experimental data in the context of biological networks, pathways and human diseases. Among other features, VP of business development at GeneGo. "We are very pleased that Exelixis chose MetaCore™ to assist their discovery endeavors." Download this press release in PDF format. PROCTER & GAMBLE LICENSES METACORE™ AND METABASE™ FROM GENEGO St. Joseph, Michigan, May 9th, 2005 - GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that Procter & Gamble Pharmaceuticals, Inc., a subsidiary of The Procter & Gamble Company (NYSE - PG), has licensed MetaCore™ and MetaBase™ from GeneGo. MetaCore™ is a manually curated, proprietary human database with the ability to work with rat, mouse, fly, yeast and worm orthologs. MetaCore™ also includes a suite of software tools for analysis in the context of pathways. MetaBase™ provides researchers with direct access to MetaCore™ content and the ability to add their own algorithms and data to the MetaCore™ schema. GeneGo's MetaCore™ platform has unique interoperability by allowing users VP Business development of GeneGo. "We are pleased that a company of the caliber of P&G recognizes the potential value that our manually curated databases and analytical tools can add to their already strong R&D programs." Download this press release in PDF format. GENEGO RELEASES METACORE™ VERSION 2.5 St. Joseph, Michigan, May 2nd, 2005 - GeneGo Inc., a leading provider of databases, software and services in systems biology, announced today the release of a major new version of its flagship data mining suite MetaCore™ 2.5. The new version features fine mapping of human metabolism, transcription regulation and signaling; novel network building algorithms, filters and statistical procedures for multi-variant interpretation of human networks in terms of canonical pathways and functional processes. Primarily a human system, these tools are also applied for analysis of rat, mouse, fly, worm and yeast data. "Over the past five years of development, we have GeneGo's VP of business development. "In version 2.5, we have substantially expanded its content and capabilities in interpretation of mammalian "interactome". The current version is a mature third generation tool, whose features reflect numerous suggestions by our customers and collaborators in academy and industry. We also continue to maintain flexibility by integrating MetaCore™ with in house and third party algorithms as well as providing flexible business models for licensing." Download this press release in PDF format. ORGANON LICENSES METACORE™ FROM GENEGO St. Joseph, Michigan, April 19th, 2005 - GeneGo, Inc., a leading provider of software and databases for syste
|
|
